Developer docs
API playgroundTry for free, no card

Search company profiles

Plus Therapeutics

Full company profile

uuid0000lus

Namestring
Plus Therapeutics
Legal namestring
PLUS THERAPEUTICS, Inc.
Company typeenum
Public
Founded yearint
1997
Descriptiontext

Plus Therapeutics is a clinical-stage pharmaceutical company founded in 1997 and publicly traded on NASDAQ under the ticker PSTV, headquartered in Houston, Texas. The company develops targeted radiotherapeutics and companion diagnostics for central nervous system (CNS) cancers and other difficult-to-treat tumors, addressing indications with limited treatment options: recurrent glioblastoma, leptomeningeal metastases, pediatric brain cancers (ependymoma, high-grade glioma), hepatocellular carcinoma, and metastatic colorectal cancer. Its proprietary platform combines Rhenium radioisotopes (Rhenium-186 and Rhenium-188) with patented BMEDA chelation chemistry and 100-nanometer nanoliposome encapsulation to deliver high-dose radiation directly to tumors while sparing healthy tissue, using convection-enhanced delivery or Ommaya reservoir administration for CNS applications.

The therapeutic pipeline is anchored by REYOBIQ (rhenium Re186 obisbemeda), a Rhenium-186 radiolabeled nanoliposome therapy currently in ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials, and by 188RNL-BAM, a Rhenium-188 radioembolization therapy that loads radiolabeled nanoliposomes into biodegradable alginate microspheres for liver cancer treatment. Through its wholly-owned subsidiary CNSide Diagnostics, LLC, Plus Therapeutics also commercializes the CNSide CSF Tumor Cell Enumeration Assay, a cerebrospinal fluid diagnostic with reported 92% sensitivity and 95% specificity across more than 11,000 tests performed at over 120 U.S. cancer institutions since 2020.

The company operates a hybrid business model combining non-dilutive grant funding—$17.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in 2022 and $3 million from the U.S. Department of Defense in 2024—with repeated equity financings, including a $15 million upsized public offering in January 2026. CNSide diagnostics generate revenue via transaction-based testing fees, with national coverage agreements in place with UnitedHealthcare, Humana, Highmark, Blue Shield of California, and Elevance Health, providing access to approximately 126 million covered lives and new PLA CPT code 0640U enabling Medicare and commercial billing from July 1, 2026. Therapeutic candidates remain clinical-stage and not commercially approved, with revenue and operating losses heavily influenced by grant timing and financing-related derivative accounting.

Short descriptiontext

Plus Therapeutics is a clinical-stage pharmaceutical company developing Rhenium-based targeted radiotherapeutics (REYOBIQ, 188RNL-BAM) and the CNSide CSF diagnostic for CNS and liver cancers, serving oncology centers, neuro-oncologists, and pediatric neuro-oncology programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted radiotherapeutics, CNS cancer therapies, radiopharmaceutical development, cancer diagnostic assays, radioembolization therapy
Industry5 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAFAH
Neuro-Oncology
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Biological Products, (No Disgnostic Substances)2836
Product category
Radiopharmaceuticals for Central Nervous System Cancers
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CNSide CSF Assay Diagnostics
TypeTransaction Fee
Description

The company generates revenue through its CNSide cerebrospinal fluid tumor cell enumeration assay for detecting leptomeningeal metastases. The diagnostic test is sold to oncology centers and hospitals with reimbursement through commercial payers and Medicare. CPT code 0640U effective July 1, 2026 enables billing.

biospace.com
2Grant Funding
TypeLicensing Royalties
Description

Plus Therapeutics receives non-dilutive funding through government grants including $17.6 million from CPRIT for leptomeningeal metastases program and $3 million from the U.S. Department of Defense for pediatric brain cancer clinical trials.

tradingview.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1CNSide CSF Assay - Reimbursement through payer agreements
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

The company has secured coverage agreements with UnitedHealthcare, Humana, Highmark, Blue Shield of California, and Elevance Health. Medicare enrollment enables billing under traditional Medicare Fee-For-Service. CPT code 0640U effective July 1, 2026 for billing.

in.investing.com
2REYOBIQ - Clinical stage therapeutic
ModelOtherBilling cadenceMulti-year contract
Notes

REYOBIQ is in clinical trials and not yet commercially available. Pricing will be determined upon FDA approval and commercialization.

in.investing.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1REYOBIQ™ (rhenium Re186 obisbemeda)
Description

Lead drug candidate - Rhenium-186 radiolabeled nanoliposome therapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

plustherapeutics.com
+2 more records
Core offering1 text field

Plus Therapeutics develops and supplies targeted radiotherapeutic drug products for rare central nervous system cancers, with a primary asset REYOBIQ (rhenium Re186 obisbemeda) in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers, and a complementary Rhenium-188 radioembolization product (188RNL-BAM) for liver cancers. Through its CNSide Diagnostics subsidiary it sells a cerebrospinal fluid tumor cell enumeration assay that aids diagnosis and treatment monitoring of leptomeningeal metastases. The portfolio is built on proprietary BMEDA chelation chemistry, 100 nm nanoliposome encapsulation, and biodegradable alginate microsphere delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CNSide assay demonstrated 92% sensitivity and 95% specificity across more than 11,000 tests at over 120 U.S. cancer institutions since 2020
+3 more records
Product overview1 text field

Plus Therapeutics operates a platform-plus-products architecture centered on targeted radiotherapeutics and companion diagnostics for CNS cancers. The core therapeutic portfolio includes REYOBIQ (rhenium Re186 obisbemeda), a Rhenium-186 radiolabeled nanoliposome therapy targeting brain and CNS cancers via convection enhanced delivery; and 188RNL-BAM, a next-generation radioembolization therapy for liver cancers. Complementing the therapeutic pipeline is CNSide Diagnostics, a wholly-owned subsidiary developing the CNSide CSF Assay Platform—a diagnostic test that enumerates tumor cells in cerebrospinal fluid to aid in managing CNS cancers and leptomeningeal metastases. The company is also developing an AI execution platform in partnership with Ephemeral Technologies to integrate and analyze proprietary longitudinal therapeutic, diagnostic, and bioinformatics datasets for precision neuro-oncology.

Product and service3 records
1REYOBIQ (rhenium Re186 obisbemeda)
CategoryTargeted Radiotherapeutic
Description

Rhenium-186 radiolabeled nanoliposome therapy designed to target brain and CNS cancers in adults and children, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers such as ependymoma and high-grade glioma. Delivered via convection enhanced delivery (CED) or Ommaya reservoir. Currently in clinical trials and not yet commercially available.

2188RNL-BAM (Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere)
CategoryTargeted Radioembolization Therapeutic
Description

Next-generation radioembolization therapy in which thousands of Rhenium-188 radiolabeled nanoliposomes are loaded into a single biodegradable alginate microsphere to treat solid organ cancers including hepatocellular carcinoma and metastatic colorectal cancer. Administered via trans-arterial radioembolization (TARE). Currently in development and not yet commercially available.

3CNSide CSF Tumor Cell Enumeration Assay
CategoryCompanion Diagnostic Assay
Description

Cerebrospinal fluid assay platform for detecting and enumerating tumor cells that have metastasized to the central nervous system. Demonstrates 92% sensitivity and 95% specificity across more than 11,000 tests at over 120 U.S. cancer institutions since 2020. Supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeTechnology or Integration
Description

Master Services Agreement for GMP manufacturing activities and technology transfer for REYOBIQ clinical supply. SpectronRx enables on-demand Rhenium-186 isotope production and drug manufacturing within the same facility, strengthening the multi-partner supply chain.

Strategic tierCoreTypeTechnology or Integration
Description

Existing manufacturing partner in the multi-partner supply chain for REYOBIQ radiopharmaceutical production.

Strategic tierCoreTypeTechnology or Integration
Description

Existing partner for Rhenium-186 isotope supply in the REYOBIQ supply chain.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Strategic partnership to develop an AI-native platform for CNS oncology. The platform will integrate, organize, and analyze Plus Therapeutics' proprietary longitudinal therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology development. Expected to deliver operational efficiencies beginning in 2026.

5ABX
Strategic tierSupportingTypeTechnology or Integration
Description

Supplier partner for raw materials and product development.

plustherapeutics.com
Strategic tierSupportingTypeTechnology or Integration
Description

Analytical testing partner for product and clinical development.

7Perceptive Informatics
Strategic tierSupportingTypeTechnology or Integration
Description

Clinical technology and software partner.

plustherapeutics.com
Strategic tierSupportingTypeTechnology or Integration
Description

Technology partner for neurosurgical and radiation planning systems.

9MURR (University of Missouri Research Reactor)
Strategic tierSupportingTypeTechnology or Integration
Description

Partner for nuclear medicine and radioisotope production capabilities.

plustherapeutics.com
10Alamo Nuclear Pharmacy
Strategic tierSupportingTypeTechnology or Integration
Description

Nuclear pharmacy partner for radiopharmaceutical preparation and dispensing.

plustherapeutics.com
Strategic tierSupportingTypeTechnology or Integration
Description

Supplier partner for pharmaceutical development and manufacturing.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensed patents and technologies for 188RNL-BAM development. Also home to key opinion leader Dr. Andrew Brenner who serves on Scientific Advisory Board.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novartis is the global leader in radioligand therapy with Pluvicto (lutetium-177 PSMA-617) for prostate cancer and Lutathera (lutetium-177 dotatate) for neuroendocrine tumors. It represents the dominant incumbent that Plus Therapeutics will compete against in radiopharmaceuticals, with substantially greater resources and commercial infrastructure.

TypeDirect peer
Description

Lantheus is a leading radiopharmaceutical-focused company with diagnostic agents (e.g., PYLARIFY for prostate cancer imaging) and an expanding therapeutic pipeline. It is a direct competitor in radiopharmaceuticals and serves the same oncology specialty distribution channels as Plus Therapeutics.

TypeDirect peer
Description

Telix is a commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents including Illuccix (PSMA imaging) and is also a current supplier of Rhenium-186 to Plus Therapeutics. It competes directly with Plus in the broader radiopharmaceutical space and has approved commercial products.

TypeBroad incumbent
Description

Bayer markets Xofigo (radium-223), an approved radiopharmaceutical for bone metastases in prostate cancer, and has broader oncology infrastructure including Nubeqa and Stivarga. Bayer represents a major incumbent in radiopharmaceuticals with established global commercial reach that could expand into CNS indications.

TypeDirect peer
Description

ITM is a German radiopharmaceutical company developing both diagnostic and therapeutic radiopharmaceuticals based on lutetium-177 and other radioisotopes, with proprietary manufacturing capabilities. It is a direct peer in the targeted radiotherapeutics space, particularly for oncology indications.

TypeDirect peer
Description

Curium is one of the largest radiopharmaceutical manufacturers globally, producing diagnostic and therapeutic nuclear medicine products. It competes with Plus in radiopharmaceutical development and has established manufacturing infrastructure across SPECT, PET, and therapeutic isotopes.

TypeEmerging player
Description

Clarity Pharmaceuticals is an emerging radiopharmaceutical company developing SAR-bisPSMA and SAR-Bombesin agents using copper-64 and copper-67 isotopes. It is an emerging player in the targeted radiopharmaceutical space with overlapping scientific approach.

TypeEmerging player
Description

Alpha-9 Oncology is an emerging radiopharmaceutical company developing targeted alpha therapies for solid tumors. It overlaps with Plus in the broader radiopharmaceutical oncology space but focuses on alpha-emitting radioisotopes rather than beta-emitters like Rhenium.

TypeDirect peer
Description

Biocept is a molecular diagnostics company specializing in liquid biopsy for detecting cancer cells, including in cerebrospinal fluid for CNS metastases. It is a direct competitor to CNSide Diagnostics in CSF-based oncology diagnostics, serving the same neuro-oncology customer base.

TypeBroad incumbent
Description

Guardant Health is a leading liquid biopsy company with broad oncology diagnostic applications including CNS cancer detection through blood and CSF-based assays. It represents a broader incumbent in oncology diagnostics with substantially greater scale and established commercial channels that could expand into leptomeningeal metastases detection.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Plus Therapeutics

Radiopharmaceuticals for Central Nervous System Cancersplustherapeutics.com

Plus Therapeutics is a clinical-stage pharmaceutical company developing Rhenium-based targeted radiotherapeutics (REYOBIQ, 188RNL-BAM) and the CNSide CSF diagnostic for CNS and liver cancers, serving oncology centers, neuro-oncologists, and pediatric neuro-oncology programs.

What Plus Therapeutics does

Plus Therapeutics is a clinical-stage pharmaceutical company founded in 1997 and publicly traded on NASDAQ under the ticker PSTV, headquartered in Houston, Texas. The company develops targeted radiotherapeutics and companion diagnostics for central nervous system (CNS) cancers and other difficult-to-treat tumors, addressing indications with limited treatment options: recurrent glioblastoma, leptomeningeal metastases, pediatric brain cancers (ependymoma, high-grade glioma), hepatocellular carcinoma, and metastatic colorectal cancer. Its proprietary platform combines Rhenium radioisotopes (Rhenium-186 and Rhenium-188) with patented BMEDA chelation chemistry and 100-nanometer nanoliposome encapsulation to deliver high-dose radiation directly to tumors while sparing healthy tissue, using convection-enhanced delivery or Ommaya reservoir administration for CNS applications.

The therapeutic pipeline is anchored by REYOBIQ (rhenium Re186 obisbemeda), a Rhenium-186 radiolabeled nanoliposome therapy currently in ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials, and by 188RNL-BAM, a Rhenium-188 radioembolization therapy that loads radiolabeled nanoliposomes into biodegradable alginate microspheres for liver cancer treatment. Through its wholly-owned subsidiary CNSide Diagnostics, LLC, Plus Therapeutics also commercializes the CNSide CSF Tumor Cell Enumeration Assay, a cerebrospinal fluid diagnostic with reported 92% sensitivity and 95% specificity across more than 11,000 tests performed at over 120 U.S. cancer institutions since 2020.

The company operates a hybrid business model combining non-dilutive grant funding—$17.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in 2022 and $3 million from the U.S. Department of Defense in 2024—with repeated equity financings, including a $15 million upsized public offering in January 2026. CNSide diagnostics generate revenue via transaction-based testing fees, with national coverage agreements in place with UnitedHealthcare, Humana, Highmark, Blue Shield of California, and Elevance Health, providing access to approximately 126 million covered lives and new PLA CPT code 0640U enabling Medicare and commercial billing from July 1, 2026. Therapeutic candidates remain clinical-stage and not commercially approved, with revenue and operating losses heavily influenced by grant timing and financing-related derivative accounting.

Plus Therapeutics firmographics

Firmographics
Name
Plus Therapeutics
Legal name
PLUS THERAPEUTICS, Inc.
Website
https://plustherapeutics.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Plus Therapeutics is a clinical-stage pharmaceutical company developing Rhenium-based targeted radiotherapeutics (REYOBIQ, 188RNL-BAM) and the CNSide CSF diagnostic for CNS and liver cancers, serving oncology centers, neuro-oncologists, and pediatric neuro-oncology programs.
Ownership category
akta.pro rank

Plus Therapeutics industry classification

Industry
Product category
Radiopharmaceuticals for Central Nervous System Cancers
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAFAH
Neuro-Oncology

Keywords

  • Targeted radiotherapeutics
  • CNS cancer therapies
  • Radiopharmaceutical development
  • Cancer diagnostic assays
  • Radioembolization therapy

Where Plus Therapeutics is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Plus Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. CNSide CSF Assay Diagnostics: The company generates revenue through its CNSide cerebrospinal fluid tumor cell enumeration assay for detecting leptomeningeal metastases. The diagnostic test is sold to oncology centers and hospitals with reimbursement through commercial payers and Medicare. CPT code 0640U effective July 1, 2026 enables billing.
  2. Grant Funding: Plus Therapeutics receives non-dilutive funding through government grants including $17.6 million from CPRIT for leptomeningeal metastases program and $3 million from the U.S. Department of Defense for pediatric brain cancer clinical trials.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goCNSide CSF Assay - Reimbursement through payer agreements
OtherMulti-year contractREYOBIQ - Clinical stage therapeutic

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Plus Therapeutics product offering

Product offering

Core offering

Plus Therapeutics develops and supplies targeted radiotherapeutic drug products for rare central nervous system cancers, with a primary asset REYOBIQ (rhenium Re186 obisbemeda) in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers, and a complementary Rhenium-188 radioembolization product (188RNL-BAM) for liver cancers. Through its CNSide Diagnostics subsidiary it sells a cerebrospinal fluid tumor cell enumeration assay that aids diagnosis and treatment monitoring of leptomeningeal metastases. The portfolio is built on proprietary BMEDA chelation chemistry, 100 nm nanoliposome encapsulation, and biodegradable alginate microsphere delivery.

Product overview

Plus Therapeutics operates a platform-plus-products architecture centered on targeted radiotherapeutics and companion diagnostics for CNS cancers. The core therapeutic portfolio includes REYOBIQ (rhenium Re186 obisbemeda), a Rhenium-186 radiolabeled nanoliposome therapy targeting brain and CNS cancers via convection enhanced delivery; and 188RNL-BAM, a next-generation radioembolization therapy for liver cancers. Complementing the therapeutic pipeline is CNSide Diagnostics, a wholly-owned subsidiary developing the CNSide CSF Assay Platform—a diagnostic test that enumerates tumor cells in cerebrospinal fluid to aid in managing CNS cancers and leptomeningeal metastases. The company is also developing an AI execution platform in partnership with Ephemeral Technologies to integrate and analyze proprietary longitudinal therapeutic, diagnostic, and bioinformatics datasets for precision neuro-oncology.

Differentiator

Problem solved

Functional benefit

Brands

  • REYOBIQ™ (rhenium Re186 obisbemeda): Lead drug candidate - Rhenium-186 radiolabeled nanoliposome therapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
  • 188RNL-BAM
  • CNSide®

Products and services

  • REYOBIQ (rhenium Re186 obisbemeda) Rhenium-186 radiolabeled nanoliposome therapy designed to target brain and CNS cancers in adults and children, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers such as ependymoma and high-grade glioma. Delivered via convection enhanced delivery (CED) or Ommaya reservoir. Currently in clinical trials and not yet commercially available.
  • 188RNL-BAM (Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere) Next-generation radioembolization therapy in which thousands of Rhenium-188 radiolabeled nanoliposomes are loaded into a single biodegradable alginate microsphere to treat solid organ cancers including hepatocellular carcinoma and metastatic colorectal cancer. Administered via trans-arterial radioembolization (TARE). Currently in development and not yet commercially available.
  • CNSide CSF Tumor Cell Enumeration Assay Cerebrospinal fluid assay platform for detecting and enumerating tumor cells that have metastasized to the central nervous system. Demonstrates 92% sensitivity and 95% specificity across more than 11,000 tests at over 120 U.S. cancer institutions since 2020. Supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

Quantifiable outcome

  • CNSide assay demonstrated 92% sensitivity and 95% specificity across more than 11,000 tests at over 120 U.S. cancer institutions since 2020
  • +3 more outcomes

Companies that use Plus Therapeutics

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Plus Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Plus Therapeutics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, strategic and supporting.

  • SpectronRxcoreTechnology or IntegrationMaster Services Agreement for GMP manufacturing activities and technology transfer for REYOBIQ clinical supply. SpectronRx enables on-demand Rhenium-186 isotope production and drug manufacturing within the same facility, strengthening the multi-partner supply chain.
  • RadiomedixcoreTechnology or IntegrationExisting manufacturing partner in the multi-partner supply chain for REYOBIQ radiopharmaceutical production.
  • Telix Pharmaceuticals / IsotherapeuticscoreTechnology or IntegrationExisting partner for Rhenium-186 isotope supply in the REYOBIQ supply chain.
  • Ephemeral TechnologiesstrategicStrategic or Co-development PartnerStrategic partnership to develop an AI-native platform for CNS oncology. The platform will integrate, organize, and analyze Plus Therapeutics' proprietary longitudinal therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology development. Expected to deliver operational efficiencies beginning in 2026.
  • ABXsupportingTechnology or IntegrationSupplier partner for raw materials and product development.
  • EurofinssupportingTechnology or IntegrationAnalytical testing partner for product and clinical development.
  • Perceptive InformaticssupportingTechnology or IntegrationClinical technology and software partner.
  • BrainlabsupportingTechnology or IntegrationTechnology partner for neurosurgical and radiation planning systems.
  • MURR (University of Missouri Research Reactor)supportingTechnology or IntegrationPartner for nuclear medicine and radioisotope production capabilities.
  • Alamo Nuclear PharmacysupportingTechnology or IntegrationNuclear pharmacy partner for radiopharmaceutical preparation and dispensing.
  • PiramalsupportingTechnology or IntegrationSupplier partner for pharmaceutical development and manufacturing.
  • The University of Texas Health Science Center at San AntoniocoreStrategic or Co-development PartnerLicensed patents and technologies for 188RNL-BAM development. Also home to key opinion leader Dr. Andrew Brenner who serves on Scientific Advisory Board.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Plus Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Novartis is the global leader in radioligand therapy with Pluvicto (lutetium-177 PSMA-617) for prostate cancer and Lutathera (lutetium-177 dotatate) for neuroendocrine tumors. It represents the dominant incumbent that Plus Therapeutics will compete against in radiopharmaceuticals, with substantially greater resources and commercial infrastructure.
  • Bayer: Bayer markets Xofigo (radium-223), an approved radiopharmaceutical for bone metastases in prostate cancer, and has broader oncology infrastructure including Nubeqa and Stivarga. Bayer represents a major incumbent in radiopharmaceuticals with established global commercial reach that could expand into CNS indications.
  • Guardant Health: Guardant Health is a leading liquid biopsy company with broad oncology diagnostic applications including CNS cancer detection through blood and CSF-based assays. It represents a broader incumbent in oncology diagnostics with substantially greater scale and established commercial channels that could expand into leptomeningeal metastases detection.

Direct peers

  • Lantheus Holdings: Lantheus is a leading radiopharmaceutical-focused company with diagnostic agents (e.g., PYLARIFY for prostate cancer imaging) and an expanding therapeutic pipeline. It is a direct competitor in radiopharmaceuticals and serves the same oncology specialty distribution channels as Plus Therapeutics.
  • Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents including Illuccix (PSMA imaging) and is also a current supplier of Rhenium-186 to Plus Therapeutics. It competes directly with Plus in the broader radiopharmaceutical space and has approved commercial products.
  • ITM Isotope Technologies Munich: ITM is a German radiopharmaceutical company developing both diagnostic and therapeutic radiopharmaceuticals based on lutetium-177 and other radioisotopes, with proprietary manufacturing capabilities. It is a direct peer in the targeted radiotherapeutics space, particularly for oncology indications.
  • Curium Pharma: Curium is one of the largest radiopharmaceutical manufacturers globally, producing diagnostic and therapeutic nuclear medicine products. It competes with Plus in radiopharmaceutical development and has established manufacturing infrastructure across SPECT, PET, and therapeutic isotopes.
  • Biocept: Biocept is a molecular diagnostics company specializing in liquid biopsy for detecting cancer cells, including in cerebrospinal fluid for CNS metastases. It is a direct competitor to CNSide Diagnostics in CSF-based oncology diagnostics, serving the same neuro-oncology customer base.

Emerging players

  • Clarity Pharmaceuticals: Clarity Pharmaceuticals is an emerging radiopharmaceutical company developing SAR-bisPSMA and SAR-Bombesin agents using copper-64 and copper-67 isotopes. It is an emerging player in the targeted radiopharmaceutical space with overlapping scientific approach.
  • Alpha-9 Oncology: Alpha-9 Oncology is an emerging radiopharmaceutical company developing targeted alpha therapies for solid tumors. It overlaps with Plus in the broader radiopharmaceutical oncology space but focuses on alpha-emitting radioisotopes rather than beta-emitters like Rhenium.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Plus Therapeutics social profiles

Digital presence

Plus Therapeutics compliance and trust

Trust signal

Compliance3 records

Plus Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Plus Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Plus Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Plus Therapeutics funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Plus Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Plus Therapeutics

What does Plus Therapeutics do?

Plus Therapeutics develops and supplies targeted radiotherapeutic drug products for rare central nervous system cancers, with a primary asset REYOBIQ (rhenium Re186 obisbemeda) in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers, and a complementary Rhenium-188 radioembolization product (188RNL-BAM) for liver cancers. Through its CNSide Diagnostics subsidiary it sells a cerebrospinal fluid tumor cell enumeration assay that aids diagnosis and treatment monitoring of leptomeningeal metastases. The portfolio is built on proprietary BMEDA chelation chemistry, 100 nm nanoliposome encapsulation, and biodegradable alginate microsphere delivery.

Is Plus Therapeutics a public or private company?

Plus Therapeutics is a public company. It is classified as public and is currently operating.

When was Plus Therapeutics founded?

Plus Therapeutics was founded in 1997. It employs 11 to 50 people.

Where is Plus Therapeutics based?

Plus Therapeutics is headquartered in Houston, United States, in the North America region.

How does Plus Therapeutics make money?

Two revenue lines are on record. CNSide CSF Assay Diagnostics are the primary driver. The others are grant Funding.

Who are Plus Therapeutics's main competitors?

Broad incumbents on record are Novartis, Bayer and Guardant Health. Direct peers are Lantheus Holdings, Telix Pharmaceuticals, ITM Isotope Technologies Munich, Curium Pharma and Biocept. Emerging players are Clarity Pharmaceuticals and Alpha-9 Oncology.

Does Plus Therapeutics have an API?

No public API is recorded for Plus Therapeutics.

What industry is Plus Therapeutics in?

Plus Therapeutics's product category is Radiopharmaceuticals for Central Nervous System Cancers. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsPlus Therapeutics, Inc. (NASDAQ:PSTV) Stock Has Consensus Price Target of $51.75Plus Therapeutics shares received a consensus 'Hold' rating with a $51.75 target, while Weiss Ratings restated a sell rating. The company missed Q2 earnings estimates with a loss of $1.31 per share and revenue of $0.41 million. Citadel Advisors acquired a new stake in the second quarter.Business & FinancialColorectal Cancer Pipeline 2026: Latest FDA Approvals, Clinical Trials, And Emerging Therapies Assessment By Delveinsight Novartis, Pharma Oncology, Purple Biotech, Plus Therapeutics, Processa PharmDelveInsight's assessment of the colorectal cancer pipeline covers 195+ companies developing 200+ therapies. The U.S. FDA approved atezolizumab for Stage III dMMR colon cancer in October 2026, while adagrasib's accelerated approval was withdrawn in September 2026.Markets DailyPlus Therapeutics, Inc. (NASDAQ:PSTV) Stock Has Average Target Price of $51.75 According to BrokeragesPlus Therapeutics stock opened at $1.95, with an average broker target of $51.75 and a mixed analyst rating. The company reported Q2 EPS of -$1.31, missing the -$0.88 consensus, and revenue of $0.41 million versus $1.11 million estimates. Citadel Advisors bought a new stake in the second quarter.BioSpaceCerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered LivesCNSide Diagnostics signed an in-network agreement with Blue Cross Blue Shield of Michigan effective September 1, 2026, to provide its CNSide CSF Tumor Cell Enumeration assay. Combined with prior agreements, CNSide now has contracted coverage for approximately 158 million commercial and Medicare Advantage lives.Markets DailyPlus Therapeutics (PSTV) Expected to Release Quarterly Earnings on ThursdayPlus Therapeutics is scheduled to release its Q2 2026 earnings results on August 13, with analysts expecting a loss of $0.88 per share and revenue of $1.11 million. The company recently reported a wider-than-expected loss in Q1 2026, while institutional investors such as Geode Capital Management and State Street Corp increased their stakes in the fourth quarter. Weiss Ratings maintains a 'sell' rating on the stock, which trades with a market capitalization of approximately $26.43 million.Ticker ReportPlus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of “Hold” from AnalystsPlus Therapeutics, Inc. (NASDAQ:PSTV) is a biopharmaceutical company developing targeted radiotherapeutics for oncology. The company has a market cap of $26.57 million and reported quarterly earnings that missed analyst estimates.Defense WorldPlus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Recommendation of “Hold” from BrokeragesSeven analysts have given Plus Therapeutics (NASDAQ:PSTV) a consensus "Hold" recommendation with an average 1-year price target of $56.40, with ratings ranging from one sell to four buy orders. The company's recent quarterly earnings missed consensus estimates, reporting an EPS of -$1.05 versus the expected -$0.85, while revenue of $1.03 million slightly exceeded analyst expectations of $0.97 million. Several institutional investors, including Geode Capital Management, State Street Corp, and Jane Street Group, have recently adjusted their positions in the company.Stock TitanPlus Therapeutics Rebrands as Cerenome, Ticker CNSY Aug. 3Plus Therapeutics, Inc. announced it will rebrand as Cerenome, Inc. and begin trading under the ticker symbol CNSY on the Nasdaq Capital Market effective August 3, 2026. The rebrand reflects the company's evolution from a therapeutics-focused organization into an integrated CNS oncology company combining precision diagnostics, targeted therapeutics, and artificial intelligence within a single platform. The company highlighted its commercially available CNSide® diagnostic platform and lead therapeutic REYOBIQ™ in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers.YahooPlus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases ConferencePlus Therapeutics, Inc. announced it will present two posters at the 2026 SNO/ASCO CNS Metastases Conference in Boston, highlighting its ReSPECT-LM clinical development program and CNSide® cerebrospinal fluid diagnostic platform. The company and its wholly owned subsidiary CNSide Diagnostics will also host a sponsored symposium on leptomeningeal metastases management. Additionally, Plus Therapeutics revealed it will formally introduce Cerenome as its new corporate identity alongside new branding for its expanded CNS cancer focus at the conference.GlobeNewswirePlus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases ConferencePlus Therapeutics, Inc. announced it will present two posters on its ReSPECT-LM clinical program and CNSide CSF diagnostic platform at the 2026 SNO/ASCO CNS Metastases Conference in Boston, Massachusetts from August 13–15, 2026, along with a sponsored symposium co-hosted by its subsidiary CNSide Diagnostics. The company also disclosed that effective August 3, 2026, it will change its corporate name to Cerenome, Inc. and begin trading under the ticker symbol CNSY. The announcements highlight the company's expanded focus on CNS cancer therapeutics and diagnostics ahead of the planned rebranding.